ViVac

Nucleic Acid-based Vaccine Platform

Health Tech & Life Sciences
Active
Pre-Funding Tel Aviv-Yafo, Israel Founded 2023
Website ↗
Last updated 2026-06-18
Total raised
Stage
Pre-Funding
Founded
2023
Headcount
3
HQ
Tel Aviv-Yafo, Israel
Sector
Health Tech & Life Sciences

About

ViVac is a revolutionary viral vaccine platform that immunizes against all viral proteins by safely and precisely mimicking actual viral infections. The platform is designed to provide more robustness and long-lasting immunity than mRNA/DNA and traditional vaccines while maintaining cost-effective production and enabling scale to meet new viral threats.

ViVac was founded by two of the world’s leading experts in synthetic biology and nano drug delivery.

Q&A

What is ViVac's primary focus?
ViVac is developing a nucleic acid-based vaccine platform designed to immunize against all viral proteins by mimicking actual viral infections, aiming for more robust and long-lasting immunity than traditional vaccines.
When was ViVac founded?
ViVac was founded in January 2023.
Where is ViVac headquartered?
ViVac is headquartered in Tel Aviv-Yafo, Israel.
Who are the founders of ViVac?
ViVac was founded by Michael Vaknin (CEO), Lior Nissim (Co-founder CSO), and Chezy Barenholtz (CTO).
In which sector does ViVac primarily operate?
ViVac operates primarily in the Health Tech & Life Sciences sector, with a focus on Pharma & Medical Biotechnology and Drug Delivery.
What is ViVac's current funding stage?
ViVac is currently in the Pre-Funding stage.

Team · 3

Founder · CEO
LinkedIn ↗
Founder · Co-founder CSO
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug Delivery
Technologies
BiologicalsGenes
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B

Highlights

1 PatentsVerified

Tags

drug-deliveryvaccines-developmentvaccinespharmaceuticalsimmunology
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)